Entry Point Capital, LLC Annexon, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 5,518 shares of ANNX stock, worth $31,728. This represents 0.04% of its overall portfolio holdings.
Number of Shares
5,518
Previous 13,618
59.48%
Holding current value
$31,728
Previous $97.6 Million
72.31%
% of portfolio
0.04%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding ANNX
# of Institutions
156Shares Held
101MCall Options Held
3.73MPut Options Held
1.3M-
Bain Capital Life Sciences Investors, LLC Boston, MA8.45MShares$48.6 Million8.47% of portfolio
-
Satter Management Co., L.P.7.41MShares$42.6 Million71.21% of portfolio
-
Bvf Inc San Francisco, CA7MShares$40.3 Million1.05% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$37.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.43MShares$37 Million2.05% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $274M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...